Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs Nutanix Inc (NTNX) Price & Performance

Davita IncTrade
Nutanix IncTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs Nutanix Inc — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while Nutanix Inc trades at $74.63 (market cap $19.78B). The key difference: Nutanix Inc is the larger of the two by market cap, and Nutanix Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Nutanix Inc for 17 Days on average.

DVANTNX
Market Cap
$11.29B$19.78B
Volume
582,2041,717,619
Sector
HealthTechnology
52-Week High
$240.96$74.63
52-Week Low
$103.87$34.41
Typical Hold Time
114 Days17 Days
Enterprise Value
$24.01B$18.94B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $177.02, up 0.14% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 15 and revenue growth from $13.64B in 2025 to projected $14.0B in 2026. Recent news highlights value-based care expansion with Humana and institutional buying by BlackRock. Technical indicators show resistance at $179 and support at $175, with RSI neutral at 59.72.

DVA presents a mixed outlook: analyst consensus targets $235.67 (33% upside) with 43% buy ratings, but technicals suggest near-term pressure. Key opportunities include consistent EPS beats and partnership growth, while risks involve rising debt-to-asset ratio (65.55% in 2025) and regulatory exposure. Net cash flow turned negative in 2025, requiring monitoring.

Nutanix Inc

Nutanix (NTNX) trades at $73.08, down 0.46% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $76.11. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.60 surpassing the $0.49 expectation. Revenue growth is robust, projected to rise from $2.54 billion in 2025 to $2.9 billion in 2026, while net income margin expanded significantly to 52.81%.

The outlook remains positive driven by strong execution, external storage partnerships, and AI growth initiatives, though high valuation multiples like EV/EBITDA of 46.22 and negative ROE of -395.76% pose risks. Investor sentiment is buoyed by recent Gartner recognitions and earnings beats, but supply chain pressures and competitive threats require monitoring.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DVA
100% Buy0% Sell
Avg holding period · 114 Days
NTNX
100% Buy0% Sell
Avg holding period · 17 Days

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA →

About Nutanix Inc

Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.

Read more on NTNX →